← All trials
NCT04860960
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 20, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2025
- First posted
- Apr 27, 2021
- Last posted
- Nov 23, 2021
- Enrollment
- 93
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cyclo Therapeutics, Inc.Lead sponsor
- Cyclo Therapeutics, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.